Cargando…
The Sec61 translocon is a therapeutic vulnerability in multiple myeloma
Multiple myeloma (MM) is an incurable malignancy characterized by the uncontrolled expansion of plasma cells in the bone marrow. While proteasome inhibitors like bortezomib efficiently halt MM progression, drug resistance inevitably develop, and novel therapeutic approaches are needed. Here, we used...
Autores principales: | Domenger, Antoine, Choisy, Caroline, Baron, Ludivine, Mayau, Véronique, Perthame, Emeline, Deriano, Ludovic, Arnulf, Bertrand, Bories, Jean‐Christophe, Dadaglio, Gilles, Demangel, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899908/ https://www.ncbi.nlm.nih.gov/pubmed/35014767 http://dx.doi.org/10.15252/emmm.202114740 |
Ejemplares similares
-
Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023) -
Mycolactone subverts immunity by selectively blocking the Sec61 translocon
por: Baron, Ludivine, et al.
Publicado: (2016) -
The Hydrophobic Core of the Sec61 Translocon Defines the Hydrophobicity Threshold for Membrane Integration
por: Junne, Tina, et al.
Publicado: (2010) -
TRC40 can deliver short secretory proteins to the Sec61 translocon
por: Johnson, Nicholas, et al.
Publicado: (2012) -
Cotranslational Folding Inhibits Translocation from Within the Ribosome–Sec61 Translocon Complex
por: Conti, Brian J., et al.
Publicado: (2014)